ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,021 to 4,040 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Denosumab vs Placebo: Number of Participants With New or Worsening Vertebral Fractures31 of 835

55 of 809

-3.1 points

-5.3 to -0.9

1,644NCT00556374

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Denosumab vs Placebo: Number of Participants With New Vertebral Fractures27 of 835

49 of 809

-2.8 points

-4.9 to -0.8

1,644NCT00556374

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds49 of 826

30 of 818

2.3 points

0.2 to 4.4

1,644NCT02556203

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds148 of 826

85 of 818

7.5 points

4.2 to 10.9

1,644NCT02556203

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds42 of 826

24 of 818

2.2 points

0.2 to 4.1

1,644NCT02556203

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With Death or First Thromboembolic Event (DTE)105 of 826

78 of 818

3.2 points

0.1 to 6.2

1,644NCT02556203

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With Primary Bleeding Event (PBE)46 of 826

31 of 818

1.8 points

-0.3 to 3.9

1,644NCT02556203

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With Net-clinical Benefit137 of 826

100 of 818

4.4 points

1.0 to 7.8

1,644NCT02556203

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Rivaroxaban (Xarelto, BAY59-7939) vs Antiplatelet: Number of Participants With Cardiovascular Death or Thromboembolic Event83 of 826

68 of 818

1.7 points

-1.1 to 4.5

1,644NCT02556203

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): deaths from any cause14 of 899

22 of 740

-1.4 points

-3.0 to 0.0

1,639NCT04571684

Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya

Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): serious adverse events41 of 899

41 of 740

-1.0 points

-3.2 to 1.1

1,639NCT04571684

Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya

10% Povidone-iodine (1% Free Iodine) in Purified Water vs 4% Chlorhexidine Gluconate (CHG) in Purified Water: deaths from any cause19 of 828

7 of 810

1.4 points

0.2 to 2.8

1,638NCT03385304

Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures

10% Povidone-iodine (1% Free Iodine) in Purified Water vs 4% Chlorhexidine Gluconate (CHG) in Purified Water: serious adverse events365 of 828

368 of 810

-1.3 points

-6.2 to 3.5

1,638NCT03385304

Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures

Observation vs Treatment: serious adverse events12 of 819

13 of 817

-0.1 points

-1.4 to 1.1

1,636NCT00000125

Ocular Hypertension Treatment Study (OHTS)

Physical Activity vs Successful Aging: Persistent Mobility Disability (Assessed Every 6 Months)120 of 818

162 of 817

-5.2 points

-8.8 to -1.5

1,635NCT01072500

The LIFE Study - Lifestyle Interventions and Independence for Elders

Physical Activity vs Successful Aging: Major Mobility Disability, Defined as Incapacity to Walk 400 Meters246 of 818

290 of 817

-5.4 points

-9.9 to -0.9

1,635NCT01072500

The LIFE Study - Lifestyle Interventions and Independence for Elders

Physical Activity vs Successful Aging: serious adverse events404 of 818

373 of 817

3.7 points

-1.1 to 8.5

1,635NCT01072500

The LIFE Study - Lifestyle Interventions and Independence for Elders

Etanercept vs nbDMARDs: Number of Participants With Chest X-Ray Prior to New Therapy183 of 194

742 of 1,441

42.8 points

37.9 to 46.4

1,635NCT01557322

Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)

Umbilical Cord Milking - Neonates vs Early Cord Clamping - Neonates: Number of Neonates Treated With Therapeutic Hypothermia (Cooling)21 of 829

35 of 806

-1.8 points

-3.7 to -0.0

1,635NCT03631940

Umbilical Cord Milking in Non-Vigorous Infants

Transdisciplinary Approach vs Multidisciplinary Approach: Depressive Symptoms20 of 437

59 of 1,195

-0.4 points

-2.5 to 2.3

1,632NCT03442322

Optimizing Care for Patients With Dementia

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=202"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=202

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00556374-6eb12190",
        "title": "Denosumab vs Placebo: Number of Participants With New or Worsening Vertebral Fractures",
        "summary": "31 of 835 against 55 of 809; risk difference -3.1 points, 95% interval -5.3 to -0.9; NCT00556374, Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy",
        "record": "/library/comparisons/NCT00556374-6eb12190",
        "nct_id": "NCT00556374",
        "kind": "outcome",
        "participants": 1644,
        "risk_difference": {
          "value": -0.030859418369688314,
          "lower": -0.05314506126130004,
          "upper": -0.009311553620660981
        },
        "group_1": "31 of 835",
        "group_2": "55 of 809",
        "difference": "-3.1 points",
        "interval": "-5.3 to -0.9",
        "trial_title": "Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy"
      },
      {
        "id": "NCT00556374-f6f756b9",
        "title": "Denosumab vs Placebo: Number of Participants With New Vertebral Fractures",
        "summary": "27 of 835 against 49 of 809; risk difference -2.8 points, 95% interval -4.9 to -0.8; NCT00556374, Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy",
        "record": "/library/comparisons/NCT00556374-f6f756b9",
        "nct_id": "NCT00556374",
        "kind": "outcome",
        "participants": 1644,
        "risk_difference": {
          "value": -0.028233273872526887,
          "lower": -0.049365346571367166,
          "upper": -0.007900284189497422
        },
        "group_1": "27 of 835",
        "group_2": "49 of 809",
        "difference": "-2.8 points",
        "interval": "-4.9 to -0.8",
        "trial_title": "Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=203",
  "request_id": "hpDSbCO5TSV-3DVa"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?